Navigation Links
European Society for Medical Oncology (ESMO) Presents Data from the,Clinical Trial of MediGene's Cancer-Killing Virus in Press,Conference

* Presentation of efficacy trends from ongoing phase I/II trial of oncolytic HSV * Poster selected by ESMO for presentation in press conference

MARTINSRIED, Germany, June 29, 2007.--The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announces that a case report from the ongoing clinical trial of MediGene's cancer killing virus will be presented in a press conference held by the European Society for Medical Oncology. Out of more than 300 posters accepted for the conference, only five were chosen for presentation in the press conference.

The event will take place on Friday, July 6, at 12:30 MEST at the ESMO conference in Lugano, Switzerland (ECLU). Dr. Axel Mescheder, Head of Clinical Research and Development at MediGene, will present the data in the press conference as well as in a poster presentation during the conference.

The phase I/II trial of NV1020 for the treatment of liver metastases of colorectal cancer is being conducted at seven leading cancer centers in the US. In September 2006, MediGene announced positive safety and efficacy data from an interim analysis of this study. The poster presented at the ESMO conference shows efficacy data in a case study for the first time.

Dr. Ulrich Delvos, Chief Operating Officer of MediGene, comments. "We are delighted and proud that the European Society for Medical Oncology has decided to present a case study from our trial in a press conference. Considering the number of studies presented on Europe's largest cancer congress, this emphasizes the innovation and the potential of this approach to fight cancer."

Journalists interested in joining the press conference please contact media@esmo.org

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgmen t of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGeneTM is a trademarks of MediGene AG

- ends -

MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company with a drug on the market. A second drug has been approved by the FDA. A third drug was recently inlicensed to market this drug in Europe. In addition, several drug candidates are currently in clinical development. MediGene also possesses innovative platform technologies.

Contact MediGene AG: Email:

investor@medigene.com

Fax: ++49 - 89 - 85 65 - 2920 Julia Hofmann/Dr. Georg Dönges, Public Relations Tel.: ++49 - 89 - 85 65 - 3317 Dr. Michael Nettersheim, Investor Relations Tel.: ++49 - 89 - 85 65 - 2946



'"/>




Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
5. Malvern initiates European user group meetings for chemical imaging
6. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
7. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. Inspire Announces Presentations at Two European Scientific Conferences
10. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
11. Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2019)... ... ... As an employer do you feel overwhelmed by all of the decisions you make when ... you best engage your employees? Do you have the budget for a best in class ... Mike Ehrle, SVP of Strategic Partnerships, Hodges-Mace and Jay Schmitt, Principal, Strategic ...
(Date:4/17/2019)... ... April 17, 2019 , ... ... named the top health Monitoring Solution tool by Security Today magazine in its ... first nomination for Knight Security in this contest recognizing outstanding government security products. ...
(Date:4/17/2019)... DANVERS, Mass. (PRWEB) , ... ... ... Technology (CST), a leading provider of antibodies, kits, and services, today announced ... will strengthen CST’s alignment with organizations that encourage science and environmental education, ...
Breaking Medicine Technology:
(Date:4/18/2019)... ... 2019 , ... The Coro Medical official sweepstakes grand prize winner of the ... As a small, volunteer-only department in rural Mississippi, Livingston entered the national contest with ... only department with life-saving equipment of this caliber in Panola County. , “We are ...
(Date:4/17/2019)... ... ... With Fentanyl overdose deaths continuing to claim lives and keeping the opioid ... for an alternative to naloxone. Researchers are presenting their findings to the American ... known by the name brand Narcan) has been utilized increasingly since the opioid crisis ...
(Date:4/17/2019)... SEOUL, South Korea (PRWEB) , ... April 17, ... ... Père-d-biz Consulting visited SHIN SUNG TK, a Korean company located in Gwangju, Korea, ... on IoT with its own patent. The two companies were in discussion of ...
(Date:4/17/2019)... ... 17, 2019 , ... Fertility Centers of Illinois ... effort to unite millions of Americans aiming to remove the stigmas and barriers ... Fertility Centers of Illinois is offering seven free physician-led webinars and free Fertility ...
(Date:4/17/2019)... ... April 17, 2019 , ... ... has just released the second installment of their two-part white paper series discussing ... new white paper reviews some of the high-level changes to the ...
Breaking Medicine News(10 mins):